文献速递炎症性肠病消化道肿瘤与早癌

戊聚糖多硫酸酯相关的不典型增生在炎症性肠病患者中的病例系列

Pentosan Polysulfate-Associated Dysplasia in Patients With Inflammatory Bowel Disease: A Case Series.
PubMed 文献 · Am J Gastroenterol · 2022-12-23

该病例系列评估了戊聚糖多硫酸酯(PPS)与炎症性肠病(IBD)或不典型增生的潜在关联。在30例使用PPS的IBD患者中,10例(33.3%)出现结肠不典型增生,其中6例(60%)因内镜下无法切除的不典型增生接受了结肠切除术,3例(10%)停用PPS后结肠炎明显改善。作者认为PPS可能在结肠炎和不典型增生的发生中起因果作用。

要点

  • 使用PPS的IBD患者中结肠不典型增生发生率高达33.3%(10/30)。
  • 60%的不典型增生患者因内镜下无法切除而需结肠切除术。
  • 停用PPS的3例患者结肠炎均获明显改善。

核心结论

  • 使用PPS的IBD患者结肠不典型增生发生率高,常需手术;停用PPS后结肠炎改善,PPS可能在结肠炎和不典型增生发生中起因果作用。

研究设计与样本

  • 病例系列,通过电子病历检索两家机构中使用PPS的IBD患者,共识别30例。

主要发现

  • 30例使用PPS的IBD患者中10例(33.3%)存在结肠不典型增生。
  • 10例不典型增生患者中6例(60%)因内镜下无法切除的不典型增生接受结肠切除术。
  • 30例中3例(10%)停用PPS,每例均获得明显临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study evaluates the potential association of pentosan polysulfate (PPS) with inflammatory bowel disease (IBD) or dysplasia. METHODS: We searched electronic medical records to identify patients with IBD using PPS. RESULTS: Ten of 30 identified patients (33.3%) had colonic dysplasia. Six of them (60%) underwent colectomy for endoscopically unresectable dysplasia. Three (10%) discontinued PPS, each with an apparent benefit. DISCUSSION: Patients with IBD at 2 institutions who had taken PPS had high rates of colonic dysplasia leading to surgery. Patients who stopped PPS showed improvement in their colitis. PPS may play a causal role in the development of colitis and dysplasia.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Anderson J, Frost S, Keyashian K, et al. Pentosan Polysulfate-Associated Dysplasia in Patients With Inflammatory Bowel Disease: A Case Series. Am J Gastroenterol. 2022. PMID: 36689730. doi:10.14309/ajg.0000000000002137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。